Batu Biologics Recruits Nobel Prize Winner Bruce Beutler

12/Aug/2018

Nobel Prize Winning Immunologist Joins Batu Biologics in Quest to “Starve the Tumor” Clinical Stage Immuno-Oncology Company Recruits Pioneer of Innate Immunity to Scientific Advisory Board Batu Biologics announced today the appointment of Nobel Prize winner Dr. Bruce Beutler to the Company’s Scientific Advisory Board. Read the full article at businesswire.com....

Read Full Article About Businesswire.com

Batu Biologics Releases Shareholder Letter

31/Aug/2018

Company discusses the clinical progress of the ValloVax Therapeutic Vaccine at the CHIPSA Hospital Samuel C. Wagner, President and CEO of Batu Biologics, has issued the following letter to the shareholders of the Company, providing a comprehensive update on the clinical progress of the ValloVax immune therapy: Read the full article at businesswire.com....

Read Full Article About Businesswire.com

Dr. Francesco Marincola Appointed as Chairman of Batu Biologics Clinical Advisory Board

24/Aug/2018

Pioneer of Tumor Immunotherapy Dr. Francesco Marincola Appointed as Chairman of Batu Biologics Clinical Advisory Board Former President of the Society for Immunotherapy of Cancer to Assist Company in Advancement of its Anti-Angiogenesis Immunotherapy Product ValloVax Batu Biologics, committed to advancement of its clinical stage cancer immunotherapeutic, ValloVax™, announced today the appointment of Dr. Francesco … Continue reading "Dr. Francesco Marincola Appointed as Chairman of Batu Biologics Clinical Advisory Board"....

Read Full Article About Businesswire.com

Batu Biologics CEO to Moderate Congressional Immunotherapy Symposium

16/Aug/2018

Batu Biologics Chief Executive Officer Samuel Wagner to Moderate Congressional Immunotherapy Symposium Congressional Candidate to Hear Concerns of Industry Leaders in Health Care Innovations Batu Biologics, a clinical stage immunotherapy company, announced today its Chief Executive Officer, Samuel Wagner, was chosen to moderate an internationally renowned panel of biotechnology companies focusing on immunotherapy. Read the … Continue reading "Batu Biologics CEO to Moderate Congressional Immunotherapy Symposium"....

Read Full Article About Businesswire.com

Batu Biologics CEO Selected for Lyfebulb Oncology Award

2/Aug/2018

Batu Biologics CEO Selected as Finalist for Lyfebulb-Helsinn Innovation Summit and Award For Oncology Eleven finalists have been chosen for the first ever Lyfebulb-Helsinn Innovation Summit & Award in Oncology Lyfebulb, a patient empowerment platform that connects patients, industry and investors to support user-driven innovation in chronic diseases, and Helsinn, today announced the names of … Continue reading "Batu Biologics CEO Selected for Lyfebulb Oncology Award"....

Read Full Article About Businesswire.com

Batu Biologics Raises $1.3 Million in Equity Crowdfunding

25/Aug/2017

Batu Biologics Successfully Completes $1.3 Million #Starvethetumor Equity Crowdfunding Campaign Company Intends to Aggressively Pursue Clinical Development of Angiogenesis Targeting Immunotherapy Product ValloVax Batu Biologics, an immuno-oncology Company dedicated to the development of its clinical stage tumor-angiogenesis targeting immunotherapy, ValloVax™, announced today the successful closure of a regulation 506(c) equity crowdfunding offering bringing in $1.3 … Continue reading "Batu Biologics Raises $1.3 Million in Equity Crowdfunding"....

Read Full Article About Businesswire.com

Batu Biologics Receives FDA IND Clearance

7/Aug/2017

Batu Biologics Receives FDA Clearance for First Multi-Pronged Immunotherapy Targeting the Blood Vessels that Feed Cancer Company’s First-in-Class Drug, ValloVax, Acts by Educating Immune System to Starve Tumors Batu Biologics, an immuno-oncology company dedicated to the development of its tumor-angiogenesis targeting immune therapy, ValloVax™, has received an Investigational New Drug (IND) approval from the U.S. … Continue reading "Batu Biologics Receives FDA IND Clearance"....

Read Full Article About Businesswire.com

Batu Chooses Unusual Path, Unusual Weapon

25/Aug/2017

Crowdfunding Part of Financial Strategy; Cancer Fight Aims to Cut Tumors’ Blood Supply When it comes to small and scrappy biotechs, Batu Biologics might take the cake. Led by a 25-year-old college dropout, Batu got its start with a $100,000 infusion of cash from a crowdfunding campaign the team launched online… the company has filed 29 … Continue reading "Batu Chooses Unusual Path, Unusual Weapon"....

Read Full Article About Businesswire.com

Batu Biologics Launches #starvethetumor Campaign

10/Aug/2017

Batu Biologics Launches #starvethetumor Crowdfunding Campaign for ValloVax Cancer Immunotherapy Company is hosting a press conference on May 11th, 2017 to discuss our strategy for ValloVax development Batu Biologics, an immuno-oncology company dedicated to studying blood vessel formation within tumors, announced today the launch of an equity crowdfunding campaign on EquityNet. Read the full article … Continue reading "Batu Biologics Launches #starvethetumor Campaign"....

Read Full Article About Businesswire.com

Batu Publishes Oncotarget Paper

3/Aug/2017

Batu Biologics Publishes Mechanistic Preclinical Data for ValloVax Company authors peer reviewed publication describing the mechanism of action of the ValloVax™ mediated immune response Batu Biologics, a biopharmaceutical company developing next generation immuno-oncology therapeutics, announced today the publication of mechanistic data for the ValloVax platform in the current issue of Oncotarget. Read the full article … Continue reading "Batu Publishes Oncotarget Paper"....

Read Full Article About Businesswire.com
1 2 3 6